Clinical Trial Update: A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the anti-amyloid monoclonal antibody MABT5102A in mild-to-moderate Alzheimer's disease has completed the study assessing bra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MABT5102A (MABT5102A)

Snippet

Sponsor: Genentech, Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED